Best Life Sciences Companies in Brandenburg, Germany
The 58 best Life Sciences companies in Brandenburg, Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Adrenomed.
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 51% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
Ranked: Best Life Sciences companies in Brandenburg
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Adrenomed Drug to treat severe sepsis | $54M | 67 mo ago | 18 18 → 17 (-6%) | 2009 | Bernd Wegener Co-Founder | — | 219 patents Therapeutic antibodies and binders targeting adrenomedullin for shock and disease treatment | 1 launch |
| 2 | SphingoTec Developer of biomarker-based diagnostic solutions for cancer, cardiovascular, and other diseases 55Growth top 20%Moat top 21%Funding top 32%Patents top 35% All 10 signals ▾Growthtop 20% Moattop 21% Fundingtop 32% Patentstop 35% Talenttop 38% Innovationtop 41% Globalbottom 40% Marketbottom 38% Techbottom 32% Newsbottom 18% Growth: Headcount 23 → 36 (+57%) across vintages · Fresh capital in last 24 mo Moat: Editorial + unicorn rating 7/10 · IP moat: 264 patents rank vs industry peers · Fliar Intelligence Index 55/100 | $36M | 23 mo ago | 36 36 → 19 (-47%) | 2002 | Andreas Bergmann Founder | Cart FunctionalityTYPO3 CMSPHP+13 | 264 patents Clinical biomarker assay development for kidney, sepsis, and neurodegenerative diagnostics | 4 launchs · 1 partnership |
| 3 | 4TEEN4 Pharmaceuticals Developer of therapeutics and diagnosticcs for cardiovascular diseases 35Patents top 23%Funding top 30%Innovation top 32%Moat top 32% All 8 signals ▾Patentstop 23% Fundingtop 30% Innovationtop 32% Moattop 32% Talentbottom 49% Globalbottom 40% Marketbottom 28% Techbottom 28% Patents: 88 patents matched (strict assignee match) · 63 filings since 2022 vs 25 in 2017-21 Funding: Raised $30.7M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $31M | 8 mo ago | — | 2013 | Andreas Bergmann Managing Director | WordPressMySQLPHP+9 | 88 patents DPP3-targeted therapeutics for shock, oxidative stress, and myocardial protection | 1 partnership |
| 4 | Kupando Developer of immunotherapeutics for cancer 11News top 32%Funding top 40%Moat top 48%Talent bottom 41% All 6 signals ▾Newstop 32% Fundingtop 40% Moattop 48% Talentbottom 41% Globalbottom 37% Marketbottom 23% News: 4 BI events in 12 mo (of 4 tracked, 2 types) · Top themes: Funding, Leadership Funding: Raised $12.6M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 11/100 | $13M | 3 mo ago | 5 | 2018 | Johanna Holldack Founder & CEO | — | — | — |
| 5 | Fiagon Clinical navigation systems for surgical applications to healthcare providers | $8M | 123 mo ago | 4 | 2007 | Dirk Mucha Co-Founder & CTO | WordPressApple iCloud MailMicrosoft 365+20 | 89 patents Image-guided spinal surgery tools and minimally invasive balloon catheter systems | — |
| 6 | Signature Diagnostics Molecular diagnostic products for cancer | $8M | 215 mo ago | 28 | 2004 | Andre Rosenthal CEO | — | 45 patents Patents concentrated in chemistry & materials | — |
| 7 | Gilupi Medical device for the isolation of circulating tumor cells. | $5M | 186 mo ago | 17 | 2006 | — | WordPressMySQLPHP+14 | 69 patents Microfluidic enrichment and detection of biomarkers in liquid samples for diagnostic testing | — |
| 8 | The Eyetronic Therapy An electrical optic nerve stimulation technology for the treatment of glaucoma | $5M | 130 mo ago | 4 | 2007 | Karl Schweitzer Co-Founder & CEO | WordPressMySQLPHP+21 | — | — |
| 9 | Pantherna Therapeutics Developer of lipid nanoparticle technologies for mRNA-based therapeutics delivery | $4M | 84 mo ago | 12 | 2017 | Klaus Giese CEO | — | 49 patents Lipid nanoparticle delivery systems for nucleic acid‑based therapeutics and vaccines. | — |
| 10 | Emperra Glucose monitoring system - devices and connected mobile & web apps | $3M | 126 mo ago | 11 | 2008 | — | — | — | — |
| 11 | BIOMES Provider of genetic testing serivces for gut health diagostics | $2M | 76 mo ago | 45 45 → 36 (-20%) | 2017 | Paul Hammer Co-Founder & CEO | Cart FunctionalityWordPressApple iCloud Mail+31 | — | — |
| 12 | Lindis Blood Care Developer of a medical device to remove cancer cells from salvaged blood | $2M | 53 mo ago | 3 | 2006 | Horst Lindhofer Co-Founder & Managing Director | — | 26 patents Purifying intraoperative salvaged blood by removing tumor cells with trifunctional antibodies | — |
| 13 | T-Cell Europe Cell-based therapies for kidney transplants patients. | $2M | 169 mo ago | 2 | 2010 | — | — | — | — |
| 14 | PAM Theragnostics Developer of therapeutic and diagnostic tools for neurodegenerative disorders | $2M | 53 mo ago | — | 2020 | Andreas Bergmann Founder & CEO | — | 26 patents Predictive biomarkers and therapeutic antibodies for immune cell therapy adverse events, plus PAM enzyme diagnostics. | — |
| 15 | Metasysx Provider of metabolomics and lipidomics services for biological samples analysis | $835K | 44 mo ago | — | 2012 | Sylwia Kierszniowska Chief Executive Officer | WordPressMySQLPHP+13 | — | — |
| 16 | OakLabs Scientific Provider of laboratory analyses and AI algorithms for customers | $610K | 138 mo ago | 9 | 2011 | Corinna Horn Co-Founder / Co-CEO / CMO | — | — | — |
| 17 | Medineering Modular robotic systems for minimally invasive head surgeries | $534K | 102 mo ago | 6 | 2014 | — | — | 68 patents Robotic surgical holding arms and endoscope guidance systems for minimally invasive procedures | — |
| 18 | BRAHMS Diagnostica Molecular diagnostic tests and biomarkers | $174K | 138 mo ago | 32,992 | 1994 | — | — | — | — |
| 19 | Oculyze Automated platform for yeast cell analysis and fermentation tracking | $118K | 86 mo ago | 11 | 2016 | Ulrich Tillich Co-Founder & Co-CEO | WordPressMySQLRedis+20 | 9 patents Portable microscope hardware for mobile imaging and on‑site sample analysis | — |
Top 12 Life Sciences companies in Brandenburg
#1
Series A · Schonefeld, Brandenburg · founded 2018 · 5 employees$12.6Mraised▾
Developer of immunotherapeutics for cancer. It offers a lead candidate KUP101 an immunostimulatory agent co-encapsulated in a liposomal formulation for the treatment of solid tumors in combination with other drugs.
- Mar 2026Series A$11.5M
- Sep 2022Series A$12.6M
#2
Series C · Hennigsdorf, Brandenburg · founded 2013$30.7Mraised▾
Developer of therapeutics and diagnosticcs for cardiovascular diseases. The company is developing a targeted therapy called Procizumab to inhibit the DPP3 pathway in cardiogenic shock. It is also using a biomarker called Dipeptidyl Peptidase 3 to identify and stratify high-risk patients.
- Nov 2025Series C$63.7M
- Feb 2024Series A—
- Dec 2019Series A$7.6M
- Oct 2018Series A$23M
#3
Series C · Hennigsdorf, Brandenburg · founded 2002 · 36 employees$36.1Mraised▾
Developer of biomarker-based diagnostic solutions for cancer, cardiovascular, and other diseases. The company is involved in the development of biomarker-based in-vitro diagnostic solutions for the treatment of critical medical conditions, such as sepsis, acute heart failure, circulatory failure, and acute kidney injury. It develops a PenKid platform that measures the levels of renal hormone enkephalin and uses it to predict creatinine levels in the near future. Bio-ADM measures levels of Adrenomedullin as a biomarker for circulatory shock and vasopressor demand. It has also developed a pro-NT biomarker that measures the levels of proneurotensin to predict the risk of obesity, cardiovascular disease, and breast cancer. It provides a vr-hGH platform that measures levels of human growth hormone to predict cardiovascular risk in men.
- Aug 2024Series C$5.5M
- Dec 2019Series B$7.6M
- Oct 2018Series A$23M
- 2018Seed—
#4
Series E · Hohen Neuendorf, Brandenburg · founded 2009 · 18 employees$53.8Mraised▾
Adrenomed focuses on developing drugs to treat severe sepsis. Sepsis involves an overactive inflammatory response to severe bacterial infection that can compromise the vascular integrity and cause tissue edema, organ dysfunction and death. Its drug adrenomedullin is a peptide with 52 amino acids and has strong vasodilator activity.
- Nov 2020Series E$26.6M
- Nov 2018Series D$27.2M
#5
Acquired · Hennigsdorf, Brandenburg · founded 2007 · 4 employees$8.5Mraised▾
Clinical navigation systems for surgical applications to healthcare providers. The system uses electromagnetic tracking matrix algorithms and pointer technology, allowing surgeons to bend instruments without compromising precision. It offers a range of products, including the CUBE virtual guidance platform for ENT and skull base surgeries. Using proprietary FlexSensor technology, it develops navigation systems for ENT, oral and maxillofacial surgery, and neurosurgery.
- Mar 2016Series D$8.5M
- 2015Series C—
- 2012Series B—
#6
Acquired · Potsdam, Brandenburg · founded 2004 · 28 employees$8Mraised▾
Signature Diagnostics develops molecular diagnostic products for cancer. Its platform technology uses next generation sequencing and proprietary algorithms for the early detection of cancer. It has two products on the market: OncoDetect for the detection of cell-free tumor DNA in blood, and OncoScout for the detection of tumor DNA from biopsy samples. In Feb 2015, Signature Diagnostics was acquired by Roche for an undisclosed sum.
- Aug 2008Series C$8M
- Jan 2008Series B—
#7
Series B · Hennigsdorf, Brandenburg · founded 2006 · 3 employees$1.9Mraised▾
Developer of a medical device to remove cancer cells from salvaged blood. The company focuses on the development of Catuvab to remove EpCAM positive tumor cells from blood, including cancer stem cells during surgery to enable autologous blood transfusion.
- Feb 2022Series B—
- Dec 2019Grant (prize money)$3.7M
- Dec 2019Series A$1.9M
#8
Series B · Kleinmachnow, Brandenburg · founded 2007 · 4 employees$5.4Mraised▾
EBS Technologies is developing Eyetronic therapy, an electrical optic nerve stimulation technology for the treatment of patients suffering from glaucoma and other conditions affecting the optic nerve. It applies gentle electrical pulses to the optic nerve cells, thereby preventing further cell degeneration and reactivating nerve tissue, resulting in restored vision. The company has received CE mark approval.
- Aug 2015Series B$1.2M
- Feb 2015Series B$281.8K
- Jun 2013Series B$3.9M
- Mar 2009Seed—
#9
Series C · Potsdam, Brandenburg · founded 2006 · 17 employees$5.4Mraised▾
Gilupi develops medical devices for the isolation of circulating tumor cells (CTCs). Its proprietary platform, the Gilupi CellCollector®, detects the presence of EpCAM-positive tumor cells in vivo by using anti-EpCAM antibodies. The isolated CTCs can then be further analyzed by any diagnostic method, including immunofluorescence, PCR, FISH, etc. Gilupi offers two products Detektor CANCER01 (DC01) recommended for CTC enumeration and Detektor CANCER02 (DC02) recommended for further downstream analysis methods
- Jan 2011Series C$4.7M
- Seed$684.4K
#10
Series A · Hennigsdorf, Brandenburg · founded 2020$1.7Mraised▾
Developer of therapeutic and diagnostic tools for neurodegenerative disorders. The company is developing a diagnostic test based on peptidylglycine α-amidating monooxygenase (PAM) enzyme to catalyze the formation of c‑terminally amidated bioactive peptide hormones and is a biomarker for early diagnosis of Alzheimer disease.
- Jan 2022Series A$1.7M
#11
Seed · Hennigsdorf, Brandenburg · founded 2017 · 12 employees$4Mraised▾
Developer of lipid nanoparticle technologies for mRNA-based therapeutics delivery. The company focuses on organ-specific and cell-selective delivery and expression of mRNA-based therapeutics. It facilitates precise pharmacological targeting of diverse tissues through tailored adjustment of lipid nanoparticles. The company's technologies guarantee efficient mRNA release in target cells for versatile therapies. The company is open to collaborations with pharmaceutical and biotech companies.
- Jul 2019Seed$4M
#12
Funding Raised · Potsdam, Brandenburg · founded 2012$835.3Kraised▾
Provider of metabolomics and lipidomics services for biological samples analysis. The company offers untargeted metabolomics and lipidomics analysis, along with data annotation services. It utilizes mass spectrometry-based technologies for profiling various samples, including plant tissues, biofluids, and cell cultures. Additional services include data analysis using unsupervised methods, machine learning models, and targeted metabolomics for absolute quantitation.
- Nov 2022Grant (prize money)$494.3K
- Jan 2017Grant (prize money)$341K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Germany
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,297 Germany-affiliated papers.
- Heidelberg University85
- German Cancer Research Center49
- Ludwig-Maximilians-Universität München48
- Technical University of Munich43
- Karlsruhe Institute of Technology33
- Gene3→29
- Mutant3→19
- Transcription (linguistics)3→16
- Messenger RNA1→14
- Immune system1→12
- Gene3→20
- Agriculture2→12
- Extracellular1→11
- Immune system1→11
- Transcriptome1→9
- Antibiotic resistance2→9
- Gene1→7
- Agriculture4→9
- Antimicrobial1→4
- Microbiome1→4
Where biotechnology is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in Germany
Germany biotechnology patent filing is cooling — 53,233 filings from 8,000 assignees (2016–2025), led by Immatics Biotechnologies, BASF Plant Science, BASF SE; annual filings 4819→4267.
- Immatics Biotechnologies4875
- BASF Plant Science4000
- BASF SE3548
- Boehringer Ingelheim INT3441
- Merck Patent3137
- MAX Planck Gesellschaft1805
- Evonik Degussa1684
- Amgen RES Munich1665
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.